Uterine cancer molecular categories now drive many treatment options. Join Dr. Gottfried Konecny, gynecologic medical oncologist and professor at UCLA Health, as he explains new treatments that span across molecular categories, with a particular emphasis on the No Specific Mutational Profile (NSMP). Of the four molecular categories for uterine cancer, over 50% of endometrial cancers are classified into the NSMP category. This is a category that includes hormone positive, HER2 negative, pMMR, MS-stable, tumor mutational burden low, p53 wildtype, and other cancer mutations that are not covered in the other three mutational categories. As a physician-scientist, Dr. Konecny translates research into novel treatment approaches for the NSMP category and beyond.
Key Takeaways From Webinar:
- Uterine cancer rates are rising and cases are expected to almost double by 2030.
- There is no “one size fits all” approach to uterine cancer treatment.
- Uterine cancer is broken into four molecular subtypes; knowing the subtype your cancer falls into is key to treating your specific type of disease.
- In the No Specific Molecular Profile (NSMP) category, estrogen receptor positive cancers are highly prevalent and the treatments are similar to those for breast cancers with this same profile.
- There have been a number of new treatments developed in the last 3-5 years, with many new ones on the horizon. In addition to immunotherapy, ADCs and PARP inhibitors are both being explored for uterine cancer.
